Evidence map›Paper›PMID 40140681›Full record

ArticleScientific reports2025

Isoniazid preventive therapy modulates Mycobacterium tuberculosis-specific T-cell responses in individuals with latent tuberculosis and type 2 diabetes.

Phillip Ssekamatte, Diana Sitenda, Rose Nabatanzi, Marjorie Nakibuule, Davis Kibirige, Andrew Peter Kyazze, David Patrick Kateete, Bernard Ssentalo Bagaya, Obondo James Sande, Reinout van Crevel and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Therapeutic Potential of Isoniazid in Inflammatory Skin Diseases: A Review.Clinical, cosmetic and investigational dermatology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Phillip SsekamatteDepartment of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda. psekamate@gmail.com.
Diana SitendaDepartment of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda.
Rose NabatanziDepartment of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda.
Marjorie NakibuuleMedical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda.
Davis KibirigeDepartment of Medicine, Uganda Martyrs Hospital Lubaga, Kampala, Uganda.
Andrew Peter KyazzeDepartment of Internal Medicine, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
David Patrick KateeteDepartment of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda.
Bernard Ssentalo BagayaDepartment of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda.
Obondo James SandeDepartment of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda.
Reinout van CrevelDepartment of Internal Medicine and Radboud Centre for Infectious Diseases, Radboud University Medical Centre, Kampala, Uganda.
Stephen CoseMedical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda.
Irene Andia BiraroMedical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus (DM) is a significant contributor to tuberculosis (TB) incidence and poor treatment outcomes. This study explored the impact of isoniazid preventive therapy (IPT) on Mycobacterium tuberculosis (Mtb)-specific T-cell memory phenotypes and function among participants with latent TB infection and DM (LTBI-DM) at baseline and after 6 months of IPT; and compared the responses to healthy controls (HC). Peripheral blood mononuclear cells were stimulated with ESAT-6 and CFP-10 peptide pools to analyse CD4

Indexed as

Antitubercular AgentsDiabetes Mellitus, Type 2IsoniazidLatent TuberculosisMycobacterium tuberculosisAdultCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleHumansImmunologic MemoryMaleMiddle AgedReceptors, CXCR5Antitubercular AgentsIsoniazidReceptors, CXCR5DiabetesFunctional profilesIsoniazid preventive treatmentLatent TB infectionMemory phenotypesT cells

Identifiers

PMID40140681
PMCPMC11947150

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.